Physician profile
John B Bowden
NPI 1831158385
$3,119.01
in general payments reported to CMS, 2019-2025
14 companies · $654 in 2025
The $654 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.83 · 2020: $207 · 2021: $312 · 2022: $568 · 2023: $710 · 2024: $621 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.62 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,385.95 | 2019-2025 | Rinvoq, Botox, Skyrizi |
| Janssen Biotech, INC. | $386.70 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $340.33 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $293.61 | 2020-2025 | Dupixent |
| Genzyme Corporation | $219.69 | 2020-2025 | |
| Revance Therapeutics, INC. | $121.41 | 2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $115.46 | 2021-2025 | |
| Lilly USA, LLC | $101.12 | 2021-2025 | Ebglyss, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.32 | 2023-2024 | Spevigo |
| Allergan, INC. | $31.49 | 2021-2022 | |
| Pfizer INC. | $28.32 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.52 | 2023 | Sotyktu |
| Leo Pharma INC. | $19.01 | 2023 | Adbry |
| Arcutis Biotherapeutics, INC. | $16.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bowden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.